Source comparison
CJC-1295 vs Ipamorelin: Research Application Comparison
Mechanism GHRH receptor agonist; albumin-bound for extended half-life Ghrelin receptor (GHSR-1a) agonist; selective secretagogue Dual pathway activation. Sustained baseline + acute pulses Complementary pathways allow supra-additive IGF-1 response without recep
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist; albumin-bound for extended half-life
- Ghrelin receptor (GHSR-1a) agonist; selective secretagogue
- Dual pathway activation. Sustained baseline + acute pulses
- Complementary pathways allow supra-additive IGF-1 response without receptor desensitization
- Half-Life
- 6–8 days
- 2 hours
- N/A
- CJC requires weekly dosing; ipamorelin requires 2–3 daily injections for pulsatile effect
- Dosing Frequency
- 1–2× weekly
- 2–3× daily
- CJC 1× weekly + ipamorelin 2× daily
- Ipamorelin's frequency burden makes standalone use impractical for long-term models
- GH Secretion Pattern
- Sustained elevation (200–300% baseline for 10–14 days)
- Acute pulse (5–10× baseline for 2–3 hours)
- Elevated baseline + superimposed pulses
- Natural GH is pulsatile; CJC alone flattens circadian rhythm, ipamorelin alone misses baseline elevation
- IGF-1 Response
- Cumulative elevation over 7–10 days; peaks at 150–200% baseline
- Transient spike (returns to baseline between doses)
- Synergistic; 3.2× greater AUC than either alone
- IGF-1 mediates most anabolic effects. Combined protocol maximizes this endpoint
- Receptor Downregulation Risk
- Minimal (GHRH receptors don't desensitize with sustained agonism)
- None (ghrelin pathway retains sensitivity indefinitely)
- Minimal
- Unlike rhGH, neither peptide suppresses endogenous GH axis. Pituitary function preserved
- Cortisol / Prolactin Effect
- None
- Earlier secretagogues (GHRP-6, hexarelin) elevated both; ipamorelin and CJC are selective
- Post-Reconstitution Stability
- 28 days at 2–8°C (95%+ potency)
- 14–21 days at 2–8°C (90%+ potency)
- Stagger reconstitution timing
- Ipamorelin degrades faster. Prepare smaller batches or accept late-cycle potency loss
- Washout Period
- 14–21 days (5× half-life for >97% clearance)
- 12–18 hours (6× half-life for >98% clearance)
- Depends on protocol end goal
- Ipamorelin clears rapidly; CJC persists for weeks. Critical for pre-surgical or crossover studies
- Cost Per Week (Typical)
- $40–60 for 2mg vial (4–8 weeks supply)
- $50–70 for 5mg vial (2–3 weeks supply at 600mcg/day)
- $90–130/week combined
- Ipamorelin's dosing frequency makes it 2–3× more expensive per week than CJC standalone
- Bottom Line
- Best for chronic IGF-1 elevation studies with minimal dosing burden
- Best for studying acute GH pulse effects or models requiring rapid washout
- Gold standard for replicating supra-physiological GH profiles without rhGH side effects
- Neither peptide 'wins'. They solve different research questions. Combined use is the current literature consensus.